tiprankstipranks
Trending News
More News >
Tengjun Biotechnology Corp. (TJBH)
OTHER OTC:TJBH
US Market
Advertisement

Tengjun Biotechnology (TJBH) Ratios

Compare
6 Followers

Tengjun Biotechnology Ratios

TJBH's free cash flow for Q2 2023 was $0.00. For the 2023 fiscal year, TJBH's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 22Dec 21Dec 20Dec 19
Liquidity Ratios
Current Ratio
1.16 0.28 0.03 0.02-
Quick Ratio
1.14 0.09 -10.81 0.02-
Cash Ratio
0.06 0.02 0.02 0.00-
Solvency Ratio
0.27 -0.03 0.68 0.32-
Operating Cash Flow Ratio
0.03 -0.03 -0.11 -0.14-
Short-Term Operating Cash Flow Coverage
0.00 0.00 -0.03 -0.15-
Net Current Asset Value
$ 6.91M$ -11.69M$ -282.50K$ -279.64K-
Leverage Ratios
Debt-to-Assets Ratio
0.00 0.00 27.45 63.46-
Debt-to-Equity Ratio
0.00 0.00 -1.00 -0.98-
Debt-to-Capital Ratio
0.00 0.00 -201.37 -39.97-
Long-Term Debt-to-Capital Ratio
0.00 0.00 0.00 0.00-
Financial Leverage Ratio
4.06 -6.40 -0.04 -0.02-
Debt Service Coverage Ratio
0.00 -85.46 -0.45 -0.20-
Interest Coverage Ratio
0.00 -148.54 -1.49 -1.94-
Debt to Market Cap
0.00 0.00 0.02 <0.01-
Interest Debt Per Share
0.00 <0.01 0.02 <0.01-
Net Debt to EBITDA
-0.17 0.67 -0.68 -6.91-
Profitability Margins
Gross Profit Margin
93.52%0.00%-94094.14%0.00%-
EBIT Margin
10.70%0.00%-233028.97%0.00%-
EBITDA Margin
10.91%0.00%-138855.17%0.00%-
Operating Profit Margin
10.70%0.00%-11128.97%0.00%-
Pretax Profit Margin
10.18%0.00%-18575.17%0.00%-
Net Profit Margin
7.56%0.00%-26021.38%0.00%-
Continuous Operations Profit Margin
7.97%0.00%-238236.55%0.00%-
Net Income Per EBT
74.25%100.09%140.09%134.03%-
EBT Per EBIT
95.13%101.26%166.91%151.58%-
Return on Assets (ROA)
19.35%-5.33%-736.93%-1866.41%-
Return on Equity (ROE)
185.04%34.14%26.71%28.69%-
Return on Capital Employed (ROCE)
107.29%32.30%11.42%14.12%-
Return on Invested Capital (ROIC)
84.05%32.33%-0.46%775.45%-
Return on Tangible Assets
19.35%-5.33%-736.93%-1866.41%-
Earnings Yield
7.08%-1.23%-0.13%-0.02%-
Efficiency Ratios
Receivables Turnover
3.24 0.00 0.33 0.00-
Payables Turnover
1.77 1.21 1.07 0.00-
Inventory Turnover
9.71 0.10 0.09 0.00-
Fixed Asset Turnover
18.63 0.00 <0.01 0.00-
Asset Turnover
2.56 0.00 0.03 0.00-
Working Capital Turnover Ratio
-62.88 0.00 >-0.01 0.00-
Cash Conversion Cycle
-56.22 3.23K 5.01K 0.00-
Days of Sales Outstanding
112.59 0.00 1.11K 0.00-
Days of Inventory Outstanding
37.58 3.54K 4.24K 0.00-
Days of Payables Outstanding
206.38 302.47 342.38 0.00-
Operating Cycle
150.17 3.54K 5.35K 0.00-
Cash Flow Ratios
Operating Cash Flow Per Share
0.02 -0.03 >-0.01 >-0.01-
Free Cash Flow Per Share
0.02 -0.04 -0.01 >-0.01-
CapEx Per Share
<0.01 0.02 <0.01 0.00-
Free Cash Flow to Operating Cash Flow
1.00 1.55 6.72 1.00-
Dividend Paid and CapEx Coverage Ratio
226.88 -1.81 -0.17 0.00-
Capital Expenditure Coverage Ratio
226.88 -1.81 -0.17 0.00-
Operating Cash Flow Coverage Ratio
0.00 0.00 -0.11 -0.15-
Operating Cash Flow to Sales Ratio
<0.01 0.00 -109.52 0.00-
Free Cash Flow Yield
0.67%-1.43%-0.37%>-0.01%-
Valuation Ratios
Price-to-Earnings (P/E) Ratio
14.13 -81.38 -766.71 -6.21K-
Price-to-Sales (P/S) Ratio
1.34 0.00 199.51K 0.00-
Price-to-Book (P/B) Ratio
11.09 -27.78 -204.80 -1.78K-
Price-to-Free Cash Flow (P/FCF) Ratio
150.15 -69.86 -271.26 -12.52K-
Price-to-Operating Cash Flow Ratio
119.00 -108.47 -1.82K -12.52K-
Price-to-Earnings Growth (PEG) Ratio
-0.07 -0.10 -8.07 -115.33-
Price-to-Fair Value
11.09 -27.78 -204.80 -1.78K-
Enterprise Value Multiple
12.13 -142.88 -144.36 -12.62K-
Enterprise Value
198.59M 60.60M 58.13M 498.55M-
EV to EBITDA
12.13 -142.88 -144.36 -12.62K-
EV to Sales
1.32 0.00 200.46K 0.00-
EV to Free Cash Flow
148.04 -69.54 -272.55 -12.53K-
EV to Operating Cash Flow
147.38 -107.96 -1.83K -12.53K-
Tangible Book Value Per Share
0.19 -0.11 -0.01 >-0.01-
Shareholders’ Equity Per Share
0.18 -0.11 -0.01 >-0.01-
Tax and Other Ratios
Effective Tax Rate
0.22 >-0.01 -0.40 -0.34-
Revenue Per Share
1.87 0.00 <0.01 0.00-
Net Income Per Share
0.14 -0.04 >-0.01 >-0.01-
Tax Burden
0.74 1.00 1.40 1.34-
Interest Burden
0.95 1.01 0.08 1.52-
Research & Development to Revenue
0.00 0.00 0.00 0.00-
SG&A to Revenue
<0.01 0.00 111.29 0.00-
Stock-Based Compensation to Revenue
0.00 0.00 0.00 0.00-
Income Quality
0.12 0.75 0.59 0.66-
Currency in USD
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis